SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat

Article citations


Y. S. Lee, Y. H. Choi, S. Y. In, T. K. Kim, K. H. Ryu, B. Y. Lee and M. G. Lee, “Pharmacokinetics of Mirodenafil and Its Two Metabolites, SK3541 and SK3544, in Spontaneously or DOCA—Salt-Induced Hypertensive Rats,” Biopharmaceutics & Drug Disposition, Vol. 32, No. 1, 2011, pp. 38-49.

has been cited by the following article:

  • TITLE: Oral Pharmacokinetics of Mirodenafil in Mexican Healthy Volunteers

    AUTHORS: Miriam del Carmen Carrasco-Portugal, Francisco Javier Flores-Murrieta, Juan Gerardo Reyes-García, Noemí Santos-Caballero

    KEYWORDS: Erectile Dysfunction; Healthy Volunteers; Mexican; Mirodenafil; Pharmacokinetic

    JOURNAL NAME: Pharmacology & Pharmacy, Vol.5 No.1, January 23, 2014

    ABSTRACT: Mirodenafil is a 5-phosphodiesterase inhibitor that is currently marketed in Korea for the treatment of erectile dysfunction; however, no information in other populations is available. It has been described that Mirodenafil is metabolized by CYP3A4, a metabolic pathway in which interethnic differences have been reported. The purpose of this study was to characterize the oral pharmacokinetics of Mirodenafil in Mexicans. Seventeen male healthy volunteers were enrolled in this study. After an overnight fast, volunteers received an oral 100 mg dose and blood samples were collected at selected times during 24 h. Plasma was stored frozen and analyzed by an HPLC method. Pharmacokinetic parameters obtained were: Cmax 331.129 ± 32.689 ng/mL, tmax 1.574 ± 0.293 h, AUC24h 883.293 ± 104.088 ng·h/mL, AUC¥ 976.477 ± 108.812 ng·h/mL and t1/2 1.807 ± 0.171 h. Parameter values observed in this study are similar to those reported in Koreans. Since efficacy and safety studies of Mirodenafil have been conducted in Koreans, it is expected that dosage regime to employ in Mexicans should be similar to the approved for Korean population.